Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Shao, F. Perros, C. Meng, G. Caramori, M. Humbert, P. C. Chou, I. Adcock, S. Wort (London, United Kingdom; Paris, France; Ferrara, Italy). Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension. Eur Respir J 2014; 44: Suppl. 58, 302

Member's Comments

No comment yet.

Related content which might interest you: Characterization of circulating CD133+ progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Endothelial microparticles and progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Vascular endothelial growth factor (VEGF) as marker of pulmonary hypertension in children with asthma Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Th17 inflammation and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Would RDW be a prognostic factor in pulmonary arterial hypertension? Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 LSC 2014 abstract - Combined effects of inflammatory mediators and BMPR2 mutation on pulmonary arterial cell function in a pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 miR-126; link between angiogenesis and exercise intolerance in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 mir-126 contribute to angiogenesis defect in pulmonary arterial hypertension right ventricle failure Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014